KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
15.79
0.00 (0.00%)
At close: Dec 24, 2025, 4:00 PM EST
15.99
+0.20 (1.27%)
Pre-market: Dec 26, 2025, 4:06 AM EST
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover KalVista Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $27.17, which forecasts a 72.07% increase in the stock price over the next year. The lowest target is $20 and the highest is $30.
Price Target: $27.17 (+72.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 4 | 4 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +77.33% | Dec 4, 2025 |
| Citizens | Citizens | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +77.33% | Nov 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +77.33% | Sep 12, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $27 → $28 | Buy | Maintains | $27 → $28 | +77.33% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +70.99% | Jul 11, 2025 |
Financial Forecast
Revenue This Year
60.78M
Revenue Next Year
184.86M
from 60.78M
Increased by 204.16%
EPS This Year
-3.09
from -3.69
EPS Next Year
-1.12
from -3.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 104.7M | 262.0M | |||
| Avg | 60.8M | 184.9M | |||
| Low | 13.1M | 99.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 331.0% | |||
| Avg | - | 204.2% | |||
| Low | - | 64.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.52 | -0.11 | |||
| Avg | -3.09 | -1.12 | |||
| Low | -3.53 | -2.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.